Drug intelligence / Profile preview

Bluetongue virus vaccine

Development stage: Preclinical
Lead developer: VAXiGEN
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

The Bluetongue virus (BTV) vaccine is a veterinary vaccine candidate currently in the research and pre-clinical stages of development by VAXiGEN. It is designed to prevent Bluetongue disease, a significant viral infection affecting ruminants such as sheep, cattle, and goats. The vaccine is built upon VAXiGEN's proprietary 'Surface Display' technology platform, which involves presenting BTV antigens on the surface of a carrier to stimulate a protective immune response in the host. This approach aims to provide an effective, indigenous solution for managing BTV outbreaks, which can have substantial economic impacts on the livestock industry.

Other names: BTV vaccineVAXiGEN BTV vaccineBluetongue disease vaccine

Beyond the preview

Go deeper on Bluetongue virus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bluetongue virus vaccine.

Explore the full profile